Clal Biotechnology Industries Ltd.

ILA 23.30As of Sun 8 Nov 2026, 12:00 UTC
TASE:CBIHealthcare
Country Israel
PE (Fwd) •••
TSR 10Y CAGR (21.23%)
Div yield —
ROE (64.25%)
Biotechnology
Beta (5Y) 0.28
PE TTM —
TSR TTM (26.27%)
Mkt cap ILS 36.55M
ROIC (5.80%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
ILA 24
1.36%
(20.60%)
Hold 10|4|4|10|0
4Q25
1Q26
2Q26
3Q26
Earnings per shareILS
0.39
0.42
0.43
0.47
24.72%
21.11%
22.07%
26.93%
RevenueILS M
3.667
3.663
3.595
3.528
(1.28%)
(2.00%)
(5.52%)
(5.45%)
Peers (US$11.42M)
Cap (US$)
PE
10.13M
—
9.333M
—
11.33M
—
Capital
TTM
5Y
10Y
Leveragex
11.52
0.309
0.244
EBIT/Intx
1.893
0.222
0.202
Own earn%
59.71
4.63
12.78
Sh yield%
26.13
43.82
44.40
Owners
Insiders/Inst%
11.85
52.41
Short interest%
1.19
SBC / revenue%
2.24
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
1–10
$1 testx
—
Incr. ROIC%
8